{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ABC%2FDTG%2F3TC+immediate+release+tablets",
    "query": {
      "intervention": "ABC/DTG/3TC immediate release tablets"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T22:36:21.795Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03016533",
      "title": "Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Dolutegravir film-coated tablets",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir film-coated dispersible tablets",
          "type": "DRUG"
        },
        {
          "name": "ABC/DTG/3TC immediate release tablets",
          "type": "DRUG"
        },
        {
          "name": "ABC/DTG/3TC film-coated dispersible tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "Up to 25 Years"
      },
      "enrollment_count": 100,
      "start_date": "2017-06-06",
      "completion_date": "2024-12-24",
      "has_results": true,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-09-23T22:36:21.795Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Fort Lauderdale, Florida • Memphis, Tennessee",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03016533"
    },
    {
      "nct_id": "NCT02738931",
      "title": "Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Dolutegravir 50 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine 300 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-05",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2017-01-18",
      "last_synced_at": "2026-09-23T22:36:21.795Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02738931"
    },
    {
      "nct_id": "NCT03760458",
      "title": "The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets",
          "type": "DRUG"
        },
        {
          "name": "Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "Up to 11 Years"
      },
      "enrollment_count": 57,
      "start_date": "2020-09-09",
      "completion_date": "2022-05-31",
      "has_results": true,
      "last_update_posted_date": "2023-06-27",
      "last_synced_at": "2026-09-23T22:36:21.795Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03760458"
    }
  ]
}